Dingell, Stupak Raise Concerns, Questions on ENHANCE Trial

Dingell, Stupak Raise Concerns, Questions on ENHANCE Trial

Call on Merck, Schering-Plough and FDA to Provide Information

Washington, D.C. – Rep. John D. Dingell (D-MI), Chairman of the Committee on Energy and Commerce, Rep. Bart Stupak (D-MI), Chairman of the Oversight and Investigations Subcommittee today wrote to Andrew von Eschenbach, Commissioner of the Food and Drug Administration (FDA), and to the CEOs of Schering-Plough Corporation and Merck & Co, Inc., requesting information about the ENHANCE study trial. The ENHANCE study compared the brand-name drug Vytorin to the generic drug simvastatin, both of which are used to treat patients with high-cholesterol. The study results show that Vytorin, which is a combination of Zetia and the generic simvastatin, resulted in no significant difference when compared to simvastatin alone.

The Committee on Energy and Commerce began an investigation into the ENHANCE trial on December 11, 2007. The investigation was launched following concerns that, although the ENHANCE trial ended in April 2006, the data had not yet been released. The results were recently released on January 14, 2008.

Suggested Articles

Galecto picked up $64 million to push its lead lung disease treatment toward an approval in Europe and fund midstage studies for its other programs.

The financing, which attracted support from Roche Venture Fund, sets Palladio up to test its vasopressin V2 receptor antagonist in a kidney disease.

A new atlas of 500,000 cardiac cells could help researchers better understand how a healthy heart operates—and what goes wrong in heart disease.